Viking Therapeutics Inc VKTX shares are trading higher on Tuesday, after Chardan initiated coverage on the company's stock with a Buy rating and $15 price target.
Viking Therapeutics is a health care service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta.
Viking Therapeutics shares trading up 4.5% at $6.63 on Tuesday. The stock has a 52-week range between $8.92 and $3.26.
Related Links:
Roche's Faster Coronavirus Test Receives FDA Emergency Use Authorization
Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
